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Incubation of rat hepatocytes with 10 mM mevalonate produces a decrease in HMG-CoA reductase activity 
and in the rate of synthesis of both monomeric and dimeric HMG-CoA reductase, and an increase in the 
rate of degradation of the monomeric form without significant change in that of the dimeric form. Since 
mevalonate promotes a short-term phospho~lation of the monomeric form without affecting the dimeric 
form, it is suggested that the mechanism of degradation of reductase is controlled by its phosphorylation 
state. 
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1. INTRODUCTION 
3-Hydroxy 3-methylglutaryl-CoA reductase (EC 
1.1.1.34), the rate-limiting enzyme of cholesterol 
and isoprenoid bios~thetic pathways [l], is bound 
to the endoplasmic reticulum of animal cells 
through 7 membrane-spanning regions [2], with its 
catalytic active center projected into the 
cytoplasm. We have proposed that there is an 
equilibrium between a monomeric form of 97 kDa 
[3] and a dimeric form composed of two 
monomers linked through a carbohydrate chain 
[4]. The dimeric form with an approximate 
molecular mass of 200 kDa has been recently con- 
firmed using a radiation mechanism for inactiva- 
tion [5]. The different rates of degradation of the 
monomeric and dimeric forms suggest that 
dimerization can be a mechanism of control of the 
enzymic activity [4]. 
* To whom correspondence should be addressed 
Abbrevjations: PAGE, polyac~lamide gel elec- 
trop&oresis; PMSF, phenyimethylsulfonyl fluoride; 
HMG-CoA, hydroxymethylglutaryl-CoA 
In several papers, mevalonate, the product of 
the reductase-catalyzed reaction, has been shown 
to decrease the enzymatic reductase activity in dif- 
ferent cell lines [6-81 and whole rat liver [9]. Here, 
we present evidence that, in rat hepatocytes, 
mevalonate changes the rate of degradation of the 
monomeric form of reductase without significantly 
altering that of the dimeric form. Since phos- 
phorylation of the reductase monomer is increased 
with respect to the control, while the dimer re- 
mains at the same phosphorylation level, we sug- 
gest that mevalonate changes the rate of degrada- 
tion of HMG-CoA reductase through a 
phosphorylation mechanism. 
2. MATERIALS AND METHODS 
Hydrox~ethyl[14C]glutaric acid,CoA,NADP+, 
glucosed-phosphate dehydrogenase and silica gel 
plates were obtained from the sources described in 
[lo]. Mevalonate was from Sigma and 32P (carrier- 
free) from Amersham, Other chemicals were ob- 
tained from the sources indicated in [4]. 
The techniques used here, namely, isolation of 
rat hepatocytes, incubation of hepatocytes with 
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t3~~]rn~~~~~~i~~~ **u~o~re~i~itation of the 
solubilized HMC-CoA reductase, SDS-PAGE and 
fluorography have been reported (41. 
The phosphorylation experiments were per- 
formed by incubating 5 x lo6 cells for 90 min in 
a final volume of 1.5 ml of low-phosphate (0.1 
MM) Hank’s buffer supplemented with amino 
acids and cofactors as described by Eagle [ 11 f to 
which 1 mCi carrier-free 32P was added. 
Thereafter, aliquots of cells with or without 10 
mM mevalonate were incubated for several periods 
of time. After solubilizat~on~ immunoprecipitation 
and SDS-PAGE, the radiola~led bands detected 
by autoradiography were cut and the radioactivity 
incorporated into protein quantitated taking ad- 
vantage of the Cerenkov effect. 
HMG-CoA reductase activity was assayed as in 
[ 121 in a preparation of hepatocytes obtained as 
follows: cells (15 x 10”) were solubilized for 30 s 
in 1 ml buffer (lola Triton X-100, 5 mM EDTA, 5 
mM EGTA, 0.1 M NaCl, 0.1 mM leupeptin, 0.01 
mM antipain, 15 pg/ml aprotinin, 2 mM PMSF, 5 
MM DTT, 0.01 M phosphate; pH 7.5). The 
suspension was then centrifuged at 12000 x g for 
15 min and the supernatant incubated for 150 min 
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Fig. I. Infhrence of mevalonate on HMG-CoA reductase 
activity. Isolated rat hepatocytes were incubated with 
(# or without (01 IO mM mevalonate. At different 
times, HMG-COG reductase activity was determined and 
is shown as a percentage of the reductase activity at zero 
time (25 pmollmin per mg protein). measured. (A) Monomer, (B) dimer. 
Fig.2. Effect of mevalonate on the synthesis of the 
monomer and dimer forms of HMG-CoA reductase. Rat 
hepatocytes were incubated with f3’S]methionine {o) or 
with a combination of [35S]met~ouiue plus mevalonate 
10 mM @I. At the indicated times, reductase from 
3 x i06 &Is was imrn~o~reci~~tat~ and the radioac- 
tivity present in the I04 and 180 kDa peptides was 
184 
3. RESULTS 
Incubation of rat hepatocytes with IO mM 
mevalonate produced a time-dependent decrease in 
HMG-CoA reductase activity reaching the max- 
imum value at 60 min (fig.1). Using im- 
munoprecipitation of a biologically radiolabelled 
enzyme, we investigated whether mevalonate af- 
fected the rate of synthesis of the monomeric and 
dimeric forms of reductase at the same level. In 
order to do so, we incubated rat hepatocytes with 
10 mM mevalonate and j3’S]methionine for dif- 
ferent periods of time, and the reductase was then 
immunoprecipitated as described in section 2. The 
results are shown in fig.2. Mevalonate appeared to 
have produced a decrease in the rate of synthesis of 
the monomeric and dimeric forms. In addition, the 
newly synthesized monomeric and dimeric reduc- 
tase incubated without mevalonate (controls) re- 
mained at the same ratio for 40 min. 
The effect of mevalonate on the degradation of 
radiolabeled reductase was determined in pulse- 
chase experiments. Cells were incubated with 
f3sS]methionine for 60 min. The cells were then 
peheted and resuspended in a medium without 
labeled methionine and with 2 mM unlabeled 
methionine and incubated with or without 10 mM 
mevalonate for different periods of time. At the 
times indicated in fig.3, the enzyme was immuno- 
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Fig.3. Influence of mevalonate on the degradation of 
monomeric and dimeric forms of HMG-CoA reductase. 
Rat hepatocytes were incubated for 60 min in the 
presence of 25 pCi [35S]methionine lo6 cells, then 
washed and resuspended in a medium containing 
unlabeled 2 mM methionine and incubated in the 
absence (0) or presence (0) of 10 mM mevalonate. At 
the indicated times, the enzyme from 4 x 10” cells was 
immunoprecipitated and the 3sS content of the 104 kDa 
(A) and 180 kDa (B) polypeptides was measured as 
described in section 2. The percentage of radioactivity 
corresponding to zero time (3634 cpm, monomer; 
24 150, dimer) is represented on the ordinate. 
precipitated and the radioactivity corresponding to 
the 180 and 104 kDa bands was quantitated. As 
can be seen in fig.3A, mevalonate decreased the 
half-life of the monomer (40 vs 70 min). Degrada- 
tion in the dimer was slightly stabilized by 
mevalonate (fig.3B). Since mevalonate had no ef- 
fect on the degradation of total radiolabeled pro- 
teins (not shown), our results indicated a specific 
effect of mevalonate on the degradation of the 
monomeric form of HMG-CoA reductase without 
significantly affecting the dimeric form. 
In addition to investigating the effect of 
mevalonate on the half-life of both monomeric 
and dimeric forms, we assayed the effect of this 
compound on the phosphorylation state of each of 
two reductases. Accordingly, we incubated 
isolated rat hepatocytes with 1 mCi “PO4 for 90 
min. Thereafter, aliquots of cells were incubated 
for different periods of time with or without 10 
mM mevalonate, and processed as described in sec- 
tion 2. Fig.4 shows that mevalonate increases the 
phosphorylation state of the monomeric reductase 
by 65% over the control in 7 min, while 
phosphorylation decreased over longer periods of 
time. Unlike the monomer, the dimer practically 
did not change its phosphorylation state in 7 min, 
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Fig.4. Effect of mevalonate on the phosphorylation of 
the monomeric and dimeric forms of HMG-CoA reduc- 
tase. Rat hepatocytes (5 x lo6 cells) were preincubated 
for 90 min in the presence of 1 mCi ‘“Pod, and further 
incubated at different times in the absence or presence of 
10 mM mevalonate. At the indicated times, the enzyme 
was immunoprecipitated from an equal aliquot of cells 
(5 x 106) and the 32P content of the 104 kDa (0) and 
180 kDa (0) polypeptides was measured as described in 
section 2. The ordinate represents the percentage of the 
ratio of cpm of the immunoprecipitated polypeptide in 
the presence of mevalonate vs cpm in its absence. 
Radioactivity corresponding to zero time: 485 cpm, 
monomer; 500 cpm, dimer. 
and over longer periods of time decreased to lower 
levels than the control. By comparing these results 
with those of fig.3, it was observed that an increase 
in phosphorylation of the monomeric reductase 
correlated with a more active rate of degradation 
(shorter half-life). The same applied to the dimer: 
small decreases in phosphorylation of the dimer 
produced by mevalonate caused significant small 
increases in the half-life of this form of HMG-CoA 
reductase. 
4. DISCUSSION 
Mevalonate has been shown to be an effective 
repressor of HMG-CoA reductase activity in 
several cell lines and whole rat liver [6-91. This 
metabolite, together with LDL, completely 
represses the expression of the gene of HMG-CoA 
reductase in compactin-treated cells [6]. However, 
the mechanism of this enhanced decrease of en- 
zyme activity after a few minutes of administration 
of mevalonate has not been explained in previous 
papers. 
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Our results show that mevalonate appears to in- 
crease the rate of degradation of the monomeric 
form, and to a lesser extent, to decrease degrada- 
tion of the dimeric form. The observation that the 
increase of phosphorylation of the monomeric 
form caused by mevalonate correlates with its 
augmented rate of degradation, and that small 
decreases of phosphorylation of the dimer with 
respect o the control induced by mevalonate also 
correlate with a small enhancement of the stability 
of this dimeric form, suggests that there is a 
mechanism for the degradation of HMG-CoA 
reductase controlled by its phosphorylation state. 
These results agree with those of Parker et al [ 131. 
These authors showed that in in vitro experiments 
phosphorylated microsomal reductase was much 
more easily degraded by the calcium-dependent 
protease calpain II than the unphosphorylated 
reductase. The correlation between phosphoryla- 
tion of enzymes and accelerated rate of degrada- 
tion has also been shown for pyruvate kinase [14] 
and fructose-l ,6-bisphosphatase [ 151. 
While it has been reported that 25hydroxy- 
cholesterol increases the degradation of reductase 
without changing its phosphorylation state [16], it 
has also been shown that cholesterol influences 
reductase degradation when its NH2 terminus is 
bound to the endoplasmic reticulum through 7 
spanning regions. The absence of binding of reduc- 
tase to the endoplasmic reticulum, as a conse- 
quence of a mutation of the reductase gene, 
prevents cholesterol-induced egradation [ 17,181. 
Independently of the fact that alternative 
mechanisms of control of reductase degradation 
may exist, the phosphorylation-dephosphoryla- 
tion cycle appears to be a control mechanism for 
reductase degradation, particularly when 
mevalonate is present in excess in the incubation 
medium. 
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